Characteristics and Outcomes of Real-World Patients with Immunotherapy-Refractory Metastatic Melanoma Referred for Evaluation for Tumor Infiltrating Lymphocyte Therapy

Key Points

• Immunotherapy-refractory patients showed varied treatment responses, highlighting the need for tailored approaches.
• Among evaluated patients, 40% exhibited significant clinical improvement after tumor infiltrating lymphocyte therapy.
• Analysis considered clinical data from multiple institutions, ensuring a broad perspective on treatment efficacy.
• Findings indicate a potential shift towards tumor infiltrating lymphocytes for individuals who do not respond to standard immunotherapy.